Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)

NCT07062588 is registered in ClinicalTrials.gov with Angitia Incorporated Limited as lead sponsor.

NCT NCT07062588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07062588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults With Type I, III, or IV Osteogenesis Imperfecta (OI)
Lead sponsor
Angitia Incorporated Limited
Phase
Phase 2
Overall status
Recruiting
Start date
December 12, 2025
Completion date
February 28, 2029
Enrollment
80 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

osteogenesis imperfecta (oi)